Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

A Cohort Study to Evaluate the Impact of Inactivated Trivalent Influenza Vaccine on the Immunogenicity, Safety and Survival of Non-small Cell Lung Cancer Patients Receiving PD-1 / PD-L1 Inhibitors

This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.

Study Overview

• Status: Not yet recruiting
• Conditions: Non Small Cell Lung Cancer; Influenza Vaccine
• Intervention / Treatment: Drug: PD-1/PD-L1 inhibitors; Biological: Inactivated trivalent influenza vaccine

Detailed Description

Lung cancer is one of the most prevalent cancers in the world. Among them, non-small cell lung cancer (NSCLC) accounts for about 85%. Immune checkpoint inhibitors such as programmed death 1(PD-1) and PD-L1 are new treatments for NSCLC. About 290,000 to 650,000 people die from respiratory illnesses caused by seasonal flu all over the world. Cancer patients are one of the high-risk groups of influenza. Although the United States, Britain, Australia have issued guidelines recommending that cancer patients be vaccinated against influenza every year, due to concerns about the immune effect and safety of flu vaccination for cancer patients, multiple countries including China have not included cancer patients into priority influenza vaccination populations. Therefore, how to further prove the immunogenicity and safety of influenza vaccine in NSCLC patients is the key to promote influenza vaccines in NSCLC patients.

This study will recruit 130 patients with NSCLC who have been treated with PD-1 / PD-L1 inhibitors for 6 months or more and 30 healthy participants. Among them, 100 NSCLC patients and 30 healthy participants will be intramuscularly inactivated with a trivalent influenza vaccine during the influenza seasons 2020-21 and 2021-22. Vaccinated participants' peripheral blood samples were collected at day0, 12 hours, day1, 2, 7, 21, 30, 60 and 6 months after vaccination. The influenza specific antibody titers, inflammatory chemokines and cytokines, antibody-dependent cellular cytotoxicity (ADCC) activity, T lymphocytes activity and the proportions of different T cells subgroups will be measured to evaluate the participants' immune response to the vaccine. In addition, for the subjects receiving the vaccine, the study will also group by age to compare the differences in immune effects between subjects aged 18-65 and subjects over 65.

At last, this project will compare immune-related adverse events (irAEs) that occurred after receiving PD-1 / PD-L1 inhibitor therapy and survival time between NSCLC patients who receive influenza vaccine and those who do not receive influenza vaccine.

• Study Type: Observational
• Enrollment (Anticipated): 160

Contacts and Locations

• Study Contact: Name: Yayi He; Phone Number: 8613818828623; Email: 2250601@qq.com

Study Locations

• China
  • Hong Kong
    • Hong Kong, Hong Kong, China
      • School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong
      • Contact: Lit Man Leo Poon, PhD.; Phone Number: 852-3917 9943; Email: llmpoon@hkucc.hku.hk
  • Shanghai
    • Shanghai, Shanghai, China, 200433
      • Shanghai Pulmonary Hospital
      • Contact: Yayi He; Phone Number: 8613818828623; Email: 2250601@qq.com
      • Principal Investigator: Yayi He, PhD, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

NSCLC patients receiving PD-1/PD-L1 inhibitors during this project

Description

Inclusion Criteria:

1. NSCLC patients were diagnosed with clear pathological classification and receive PD-1 / PD-L1 inhibitor treatment during this project.
2. NSCLC patients have the exact start and end time of PD-1 / PD-L1 inhibitor and / or the vaccination time and follow-up information.
3. The healthy participants are not in an immunosuppressive state, such as cancer, HIV, autoimmune diseases, and long-term use of immunosuppressive drugs.
4. The healthy participants have exact vaccination time.
5. All participants have complete clinical and laboratory diagnostic data.
6. All participants are 18-75 years, regardless of gender.
7. All participants have agreed and signed the consent form before enrollment.

Exclusion Criteria:

1. Patients with unclear diagnosis of lung cancer were excluded.
2. Patients with incomplete clinical data or incomplete follow-up records.
3. Patients without signed informed consent.
4. Patient has received blood transfusion within three months.
5. Patients with HIV, Hepatitis B and Hepatitis C infections.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Vaccinated NSCLC group; This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).	Drug: PD-1/PD-L1 inhibitors; Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.; Other Names: PD-1/PD-L1 blockades; PD-1 monoclonal antibodies; PD-L1 monoclonal antibodies; Biological: Inactivated trivalent influenza vaccine; Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.; Other Names: Flu Vaccines; Influenza Virus Vaccines; Influenza Vaccine, Trivalent; Vaccine, Trivalent Influenza; Flu Shot
Vaccinated Health group; This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).	Biological: Inactivated trivalent influenza vaccine; Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.; Other Names: Flu Vaccines; Influenza Virus Vaccines; Influenza Vaccine, Trivalent; Vaccine, Trivalent Influenza; Flu Shot
Unvaccinated NSCLC group; This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).	Drug: PD-1/PD-L1 inhibitors; Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.; Other Names: PD-1/PD-L1 blockades; PD-1 monoclonal antibodies; PD-L1 monoclonal antibodies

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)	The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).	Day 0 after vaccination
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)	The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).	Day 2 after vaccination
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)	The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).	Day 7 after vaccination
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)	The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).	Day 21 after vaccination
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)	The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).	Day 30 after vaccination
Titer of neutralization antibody	Titer of neutralization antibody is measured by neutralization test.	Day 0 after vaccination
Titer of neutralization antibody	Titer of neutralization antibody is measured by neutralization test.	Day 21 after vaccination
Titer of neutralization antibody	Titer of neutralization antibody is measured by neutralization test.	Day 30 after vaccination
Titer of neutralization antibody	Titer of neutralization antibody is measured by neutralization test.	Day 60 after vaccination
Titer of neutralization antibody	Titer of neutralization antibody is measured by neutralization test.	Month 6 after vaccination
Multiple chemokine and cytokine levels in peripheral blood	IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.	Day 0 after vaccination
Multiple chemokine and cytokine levels in peripheral blood	IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.	12 hours after vaccination
Multiple chemokine and cytokine levels in peripheral blood	IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.	Day 1 after vaccination
Multiple chemokine and cytokine levels in peripheral blood	IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.	Day 2 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Day 0 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	12 hours after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Day 1 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Day 2 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Day 7 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Day 21 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Day 30 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Day 60 after vaccination
The numbers and proportions of T lymphocyte subpopulations in peripheral blood	The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.	Month 6 after vaccination
Peripheral T cell activation and proliferation	The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.	Day 0 after vaccination
Peripheral T cell activation and proliferation	The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.	Day 30 after vaccination
Peripheral T cell activation and proliferation	The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.	Day 60 after vaccination
Peripheral T cell activation and proliferation	The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.	Month 6 after vaccination
Antibody-dependent cellular cytotoxicity (ADCC)	The ADCC activities of NK-92 cells cultured by the sera from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.	Day 0 after vaccination
Antibody-dependent cellular cytotoxicity (ADCC)	The ADCC activities of NK-92 cells cultured by the sera collected from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.	Day 30 after vaccination
Antibody-dependent cellular cytotoxicity (ADCC)	The ADCC activities of NK-92 cells cultured by the sera collected from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.	Day 60 after vaccination
Antibody-dependent cellular cytotoxicity (ADCC)	The ADCC activities of NK-92 cells cultured by the sera collected from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.	Month 6 after vaccination
Immune-related adverse events (irAEs)	The performances and the grades of irAEs according to Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0) and their correlation with vaccination.	June 2020- June 2023
Progression-free Survival (PFS)	PFS is calculated as the time from from PD-1/PD-L1 inhibitor starting to the disease progression or the death from any cause.	June 2020- June 2023 (3 year)
Overall Survival (OS)	OS is calculated as the time from PD-1/PD-L1 inhibitor starting to the death from any cause.	June 2020- June 2023 (3 year)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	The proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases of complete response (CR) and partial response (PR) according to Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1).	June 2020- June 2023 (3 year)
Disease Control Rate (DCR)	The proportion of patients achieve CR or PR or stable disease (SD) after PD-1/PD-L1 inhibitor treatment according to RECIST 1.1.	June 2020- June 2023 (3 year)
Time to Treatment Failure (TFF)	The time from the start of PD-1/PD-L1 inhibitor to the withdrawal of the trial. The reasons for withdrawal include the patient's voluntary withdrawal, disease progression, adverse events and even deaths.	June 2020- June 2023 (3 year)

Collaborators and Investigators

• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
• Collaborators: The University of Hong Kong
• Investigators: Principal Investigator: Yayi He, PhD, MD, Shanghai Pulmonary Hospital, Shanghai, China

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2020
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): May 31, 2023

Study Registration Dates

• First Submitted: April 9, 2020
• First Submitted That Met QC Criteria: April 20, 2020
• First Posted (Actual): April 21, 2020

Study Record Updates

• Last Update Posted (Actual): April 21, 2020
• Last Update Submitted That Met QC Criteria: April 20, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Non-Small Cell Lung Cancer; Influenza Vaccine; PD-1 Receptor; Programmed Cell Death 1 Ligand 1
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Orthomyxoviridae Infections; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Influenza, Human; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Immunologic Factors; Antibodies; Vaccines; Immunoglobulins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors
• Other Study ID Numbers: TIV-NSCLC-PD1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No